首页|Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4?
Could COVID-19 anosmia and olfactory dysfunction trigger an increased risk of future dementia in patients with ApoE4?
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
The association of the coronavirus disease 2019 (COVID-19) with significant neurological and neuropsychiatric complications has been increasingly reported， both during the acute illness and in its aftermath。 However， due to the short duration of patient follow up until now， it is not clear whether this infection will be associated with longer-term neurological and/or neuropsychiatric sequelae。 In particular， the question of whether COVID-19 will be associated with an increased risk and rate of future dementia remains open and subject to speculation。 During the course of the COVID-19 pandemic， an increasing number of patients have reported sudden anosmia or other olfactory dysfunction as concurrent symptoms。 The possibility that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reach the brain via the olfactory nerve or an upper nasal trancribrial route is an interesting working hypothesis。 Among the identified genetic risk factors for Late-onset Alzheimer's disease (LOAD)， Apo E4 is one of the strongest and most frequent。 People carrying one or two copies of the e4 allele of Apo E4 have significant odor recognition deficits in comparison to those not carrying this haplotype。
COVID-19SARS-CoV-2AnosmiaAlzheimer's diseaseDementiaApolipoprotein E
NSTL
Elsevier
